Immunome Inc Share Price Today: Live Updates & Key Insights

Immunome Inc share price today is $20.11, up -3.94%. The stock opened at $21.14 against the previous close of $20.83, with an intraday high of $21.24 and low of $20.015.

Immunome Inc Share Price Chart

Immunome Inc

us-stock
To Invest in {{usstockname}}
us-stock

Immunome Inc Share Price Performance

$20.11 -0.0394(-3.94%) IMNM at 23 Mar 2026 01:39 PM Biotechnology
Lowest Today 20.015
Highest Today 21.24
Today’s Open 21.14
Prev. Close 20.83
52 Week High 27.65
52 Week Low 5.15
Day’s Range: Low 20.015 High 21.24
52-Week Range: Low 5.15 High 27.65
1 day return -
1 Week return -1.52
1 month return -8.03
3 month return -9.03
6 month return +105.43
1 year return +146.22
3 year return +276.5
5 year return -46.4
10 year return -

Immunome Inc Institutional Holdings

FMR Inc 14.63

T. Rowe Price Investment Management,Inc. 7.44

Fidelity Growth Compy Commingled Pl S 5.47

Vanguard Group Inc 5.34

BlackRock Inc 5.15

T. Rowe Price Small-Cap Stock 4.64

T. Rowe Price US Small-Cap Core Equity 4.53

Redmile Group, LLC 4.44

Point72 Asset Management, L.P. 4.26

Enavate Sciences GP, LLC 4.22

PRIMECAP Management Company 4.14

Fidelity Growth Company Fund 3.98

PRIMECAP Odyssey Aggressive Growth 3.37

T. Rowe Price Associates, Inc. 3.31

Driehaus Capital Management LLC 3.28

Vanguard Total Stock Mkt Idx Inv 2.77

EcoR1 Capital, LLC 2.52

T. Rowe Price Instl Small-Cap Stock 2.51

State Street Corp 2.48

Geode Capital Management, LLC 2.09

T. Rowe Price U.S. SC Core Eq Tr-D 2.09

iShares Russell 2000 ETF 2.01

Fidelity Select Biotechnology 1.88

Jefferies Financial Group Inc 1.86

State Street® SPDR® S&P® Biotech ETF 1.68

Morgan Stanley - Brokerage Accounts 1.62

Citadel Advisors Llc 1.54

Sofinnova Ventures 1.43

Woodline Partners LP 1.39

T. Rowe Price Health Sciences 1.37

Balyasny Asset Management LLC 1.26

Readystate Asset Management LP 1.17

Fidelity Growth Company K6 1.16

Fidelity Series Growth Company 1.08

Vanguard Institutional Extnd Mkt Idx Tr 0.99

JPM Global Healthcare C (acc) USD 0.95

T. Rowe Price Small-Cap Value 0.87

Fidelity Small Cap Index 0.81

JPMorgan Small Cap Growth A 0.76

iShares Russell 2000 Growth ETF 0.69

Immunome Inc Market Status

Strong Buy: 7

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Immunome Inc Fundamentals

Market Cap 2263.80 M

PB Ratio 3.7168

PE Ratio 0.0

Enterprise Value 1616.43 M

Total Assets 683.19 M

Volume 5731109

Immunome Inc Company Financials

Annual Revenue FY23:10192000 10.2M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-21958000 -22.0M, FY22:-37513000 -37.5M, FY21:-24469000 -24.5M, FY20:-17120000 -17.1M, FY19:-10550000 -10.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:4015000 4.0M, Q1/2025:2926000 2.9M, Q3/2024:2910000 2.9M, Q2/2024:2364000 2.4M

Quarterly Profit Q3/2025:-49193000 -49.2M, Q2/2025:3295000 3.3M, Q1/2025:2926000 2.9M, Q3/2024:2910000 2.9M, Q2/2024:1691000 1.7M

Quarterly Net worth Q3/2025:-57457000 -57.5M, Q2/2025:-43397000 -43.4M, Q1/2025:-41640000 -41.6M, Q3/2024:-47100000 -47.1M, Q2/2024:-36122000 -36.1M

About Immunome Inc & investment objective

Company Information Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Organisation Biotechnology

Employees 177

Industry Biotechnology

CEO Dr. Clay B. Siegall Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Immunome Inc FAQs

What is the share price of Immunome Inc today?

The current share price of Immunome Inc is $20.11.

Can I buy Immunome Inc shares in India?

Yes, Indian investors can buy Immunome Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Immunome Inc shares in India?

You can easily invest in Immunome Inc shares from India by:

Can I buy fractional shares of Immunome Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Immunome Inc?

Immunome Inc has a market cap of $2263.80 M.

In which sector does Immunome Inc belong?

Immunome Inc operates in the Biotechnology sector.

What documents are required to invest in Immunome Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Immunome Inc?

The PE ratio of Immunome Inc is N/A and the PB ratio is 3.72.